Cécile Rouzier
French Institute of Health and Medical Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cécile Rouzier.
American Journal of Medical Genetics Part A | 2007
Aline Cano; Cécile Rouzier; Sophie Monnot; Brigitte Chabrol; J. Conrath; P. Lecomte; Bruno Delobel; P. Boileau; René Valéro; Vincent Procaccio; Véronique Paquis-Flucklinger; Bernard Vialettes
Mutations in the WFS1 gene have been reported in Wolfram syndrome (WS), an autosomal recessive disorder defined by early onset of diabetes mellitus (DM) and progressive optic atrophy. Because of the low prevalence of this syndrome and the recent identification of the WFS1 gene, few data are available concerning the relationships between clinical and molecular aspects of the disease. Here, we describe 12 patients from 11 families with WS. We report on eight novel (A214fsX285, L293fsX303, P346L, I427S, V503fsX517, R558C, S605fsX711, P838L) and seven previously reported mutations. We also looked for genotype–phenotype correlation both in patients included in this study and 19 additional WS patients that were previously reported. Subsequently, we performed a systematic review and meta‐analysis of five published clinical and molecular studies of WFS1 for genotype–phenotype correlation, combined with our current French patient group for a total of 96 patients. The presence of two inactivating mutations was shown to predispose to an earlier age of onset of both DM and optic atrophy. Moreover, the clinical expression of WS was more complete and occurred earlier in patients harboring no missense mutation.
Mitochondrion | 2011
Konstantina Fragaki; Aline Cano; Jean-François Benoist; Odile Rigal; Annabelle Chaussenot; Cécile Rouzier; Sylvie Bannwarth; Céline Caruba; Brigitte Chabrol; Véronique Paquis-Flucklinger
The role of a secondary respiratory chain deficiency as an additional mechanism to intoxication, leading to development of long-term energy-dependent complications, has been recently suggested in patients with propionic acidemia (PA). We show for the first time a coenzyme Q(10) (CoQ(10)) functional defect accompanied by a multiple organ oxidative phosphorylation (OXPHOS) deficiency in a child who succumbed to acute heart failure in the absence of metabolic stress. Quinone-dependent activities in the liver (complex I+III, complex II+III) were reduced, suggesting a decrease in electron transfer related to the quinone pool. The restoration of complex II+III activity after addition of exogenous ubiquinone to the assay system suggests CoQ(10) deficiency. Nevertheless, we disposed of insufficient material to perform direct measurement of CoQ(10) content in the patients liver. Death occurred before biochemical diagnosis of OXPHOS deficiency could be made. However, this case highlights the usefulness of rapidly identifying CoQ(10) defects secondary to PA since this OXPHOS disorder has a good treatment response which could improve heart complications or prevent their appearance. Nevertheless, further studies will be necessary to determine whether CoQ(10) treatment can be useful in PA complications linked to CoQ(10) deficiency.
Human Molecular Genetics | 2017
Cécile Rouzier; David Moore; Cécile Delorme; Sandra Lacas-Gervais; Samira Ait-El-Mkadem; Konstantina Fragaki; Florence Burté; Valérie Serre; Sylvie Bannwarth; Annabelle Chaussenot; Martin Catala; Patrick Yu-Wai-Man; Véronique Paquis-Flucklinger
&NA; Wolfram syndrome (WS) is a progressive neurodegenerative disease characterized by early‐onset optic atrophy and diabetes mellitus, which can be associated with more extensive central nervous system and endocrine complications. The majority of patients harbour pathogenic WFS1 mutations, but recessive mutations in a second gene, CISD2, have been described in a small number of families with Wolfram syndrome type 2 (WFS2). The defining diagnostic criteria for WFS2 also consist of optic atrophy and diabetes mellitus, but unlike WFS1, this phenotypic subgroup has been associated with peptic ulcer disease and an increased bleeding tendency. Here, we report on a novel homozygous CISD2 mutation (c.215A > G; p.Asn72Ser) in a Moroccan patient with an overlapping phenotype suggesting that Wolfram syndrome type 1 and type 2 form a continuous clinical spectrum with genetic heterogeneity. The present study provides strong evidence that this particular CISD2 mutation disturbs cellular Ca2+ homeostasis with enhanced Ca2+ flux from the ER to mitochondria and cytosolic Ca2+ abnormalities in patient‐derived fibroblasts. This Ca2+ dysregulation was associated with increased ER‐mitochondria contact, a swollen ER lumen and a hyperfused mitochondrial network in the absence of overt ER stress. Although there was no marked alteration in mitochondrial bioenergetics under basal conditions, culture of patient‐derived fibroblasts in glucose‐free galactose medium revealed a respiratory chain defect in complexes I and II, and a trend towards decreased ATP levels. Our results provide important novel insight into the potential disease mechanisms underlying the neurodegenerative consequences of CISD2 mutations and the subsequent development of multisystemic disease.
European Journal of Human Genetics | 2014
Cécile Rouzier; Annabelle Chaussenot; Valérie Serre; Konstantina Fragaki; Sylvie Bannwarth; Samira Ait-El-Mkadem; Shahram Attarian; Elsa Kaphan; Aline Cano; Emilien Delmont; Sabrina Sacconi; Bénédicte Mousson de Camaret; Marlène Rio; Anne-Sophie Lebre; Claude Jardel; Romain Deschamps; Christian Richelme; Jean Pouget; Brigitte Chabrol; Véronique Paquis-Flucklinger
Polymerase gamma (POLG) is the gene most commonly involved in mitochondrial disorders with mitochondrial DNA instability and causes a wide range of diseases with recessive or dominant transmission. More than 170 mutations have been reported. Most of them are missense mutations, although nonsense mutations, splice-site mutations, small deletions and insertions have also been identified. However, to date, only one large-scale rearrangement has been described in a child with Alpers syndrome. Below, we report a large cohort of 160 patients with clinical, molecular and/or biochemical presentation suggestive of POLG deficiency. Using sequencing, we identified POLG variants in 22 patients (18 kindreds) including five novel pathogenic mutations. Two patients with novel mutations had unusual clinical presentation: the first exhibited an isolated ataxic neuropathy and the second was a child who presented with endocrine signs. We completed the sequencing step by quantitative multiplex PCR of short fluorescent fragments (QMPSF) analysis in 37 patients with either only one POLG heterozygous variant or a family history suggesting a dominant transmission. We identified a large intragenic deletion encompassing part of intron 21 and exon 22 of POLG in a child with refractory epilepsia partialis continua. In conclusion, we describe the first large French cohort of patients with POLG mutations, expanding the wide clinical and molecular spectrum observed in POLG disease. We confirm that large deletions in the POLG gene are rare events and we highlight the importance of QMPSF in patients with a single heterozygous POLG mutation, particularly in severe infantile phenotypes.
Molecular Genetics and Metabolism | 2017
Konstantina Fragaki; Annabelle Chaussenot; Audrey Boutron; Sylvie Bannwarth; Cécile Rouzier; Brigitte Chabrol; Véronique Paquis-Flucklinger
Patients carrying Acyl-CoA dehydrogenase 9 (ACAD9) mutations reported to date mainly present with severe hypertrophic cardiomyopathy and isolated complex I (CI) dysfunction. Here we report a novel ACAD9 mutation in a young girl presenting with severe hypertrophic cardiomyopathy, isolated CI deficiency and interestingly multiple respiratory chain complexes assembly defects. We show that ACAD9 analysis has to be performed in first intention in patients presenting with cardiac hypertrophy even in the presence of multiple assembly defects.
European Journal of Human Genetics | 2016
Mariya Moosajee; Patrick Yu-Wai-Man; Cécile Rouzier; Maria Bitner-Glindzicz; Richard Bowman
1. Name of the disease (synonyms) Wolfram syndrome. 2. OMIM# of the disease 222300 and 604928. 3. Name of the analysed genes or DNA/chromosome segments WFS1 and CISD2. 4. OMIM# of the gene(s) WFS1 MIM# 606201; CISD2 MIM# 611507. Review of the analytical and clinical validity as well as of the clinical utility of DNA-based testing for mutations in the WFS1 and CISD2 gene(s) in ⊠ diagnostic, ⊠ predictive and ⊠ prenatal settings and for ⊠ risk assessment in relatives.
Neurology Genetics | 2018
Annabelle Chaussenot; Cécile Rouzier; Konstantina Fragaki; Sabrina Sacconi; Samira Ait-El-Mkadem; Véronique Paquis-Flucklinger; Sylvie Bannwarth
Archive | 2015
Samira Ait-El-Mkadem; Annabelle Chaussenot; Sylvie Bannwarth; Cécile Rouzier; Véronique Paquis-Flucklinger
Archive | 2015
Samira Ait-El-Mkadem; Annabelle Chaussenot; Sylvie Bannwarth; Cécile Rouzier; Véronique Paquis-Flucklinger
Archive | 2015
Samira Ait-El-Mkadem; Annabelle Chaussenot; Sylvie Bannwarth; Cécile Rouzier; Véronique Paquis-Flucklinger